{"id":"rt-cddp-5-fu","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-15%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RT (radiation therapy) targets rapidly dividing cancer cells by damaging their DNA, while CDDP (cisplatin) interferes with DNA repair mechanisms, making it difficult for cancer cells to repair DNA damage. 5-FU (5-fluorouracil) is a thymidylate synthase inhibitor that disrupts DNA synthesis, further contributing to cell death.","oneSentence":"RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:02.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT02135042","phase":"PHASE2, PHASE3","title":"Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-04-21","conditions":"Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma","enrollment":685},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03070366","phase":"PHASE2","title":"Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-09-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":78},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT00324415","phase":"PHASE2","title":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Anal Cancer","enrollment":45},{"nctId":"NCT04456322","phase":"PHASE3","title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-17","conditions":"Nasopharyngeal Carcinoma","enrollment":381},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04747054","phase":"PHASE3","title":"Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-01","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":102},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT02556762","phase":"PHASE3","title":"Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer","status":"UNKNOWN","sponsor":"Chuangzhen Chen","startDate":"2015-08","conditions":"Esophageal Cancer","enrollment":202},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT03306121","phase":"PHASE3","title":"TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2017-11-13","conditions":"Nasopharyngeal Carcinoma","enrollment":322},{"nctId":"NCT03617913","phase":"PHASE2","title":"Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-19","conditions":"Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8","enrollment":2},{"nctId":"NCT00274937","phase":"PHASE3","title":"Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02-20","conditions":"Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","enrollment":111},{"nctId":"NCT04480190","phase":"PHASE1","title":"Neoadjuvant Therapy in Biliary Adenocarcinoma","status":"WITHDRAWN","sponsor":"Jordan Kharofa","startDate":"2021-02-04","conditions":"Cholangiocarcinoma, Biliary Cancer","enrollment":""},{"nctId":"NCT01889303","phase":"PHASE2","title":"Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT01126216","phase":"PHASE3","title":"Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-06","conditions":"Head and Neck Cancer","enrollment":221},{"nctId":"NCT00721513","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT03114280","phase":"PHASE1, PHASE2","title":"Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)","status":"WITHDRAWN","sponsor":"Centre Antoine Lacassagne","startDate":"2019-03-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":""},{"nctId":"NCT00828386","phase":"PHASE3","title":"Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-01","conditions":"Nasopharyngeal Cancers","enrollment":83},{"nctId":"NCT01608464","phase":"PHASE2","title":"Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2012-05","conditions":"Carcinoma of Esophagus","enrollment":170},{"nctId":"NCT00055601","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-12","conditions":"Bladder Cancer","enrollment":97},{"nctId":"NCT00408694","phase":"PHASE2","title":"Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-12-13","conditions":"Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7","enrollment":46},{"nctId":"NCT03366883","phase":"PHASE3","title":"Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02-01","conditions":"Esophageal Cancer Stage IIB, Esophageal Cancer Stage III","enrollment":420},{"nctId":"NCT00999700","phase":"PHASE3","title":"Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2009-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":282},{"nctId":"NCT00069953","phase":"PHASE2","title":"Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-09","conditions":"Esophageal Cancer","enrollment":43},{"nctId":"NCT00580983","phase":"NA","title":"Optimized Intensity Modulated Irradiation for Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2003-08","conditions":"Head and Neck Cancer","enrollment":90},{"nctId":"NCT00544362","phase":"PHASE1, PHASE2","title":"Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2007-07","conditions":"Esophageal Cancer","enrollment":33},{"nctId":"NCT00599131","phase":"PHASE2","title":"Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-08","conditions":"Cancer of Larynx","enrollment":4},{"nctId":"NCT00002735","phase":"PHASE2","title":"SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"1996-04","conditions":"Head and Neck Cancer","enrollment":68},{"nctId":"NCT01086826","phase":"PHASE3","title":"Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Associazione Volontari Pazienti Oncologici","startDate":"2008-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":320},{"nctId":"NCT00215514","phase":"EARLY_PHASE1","title":"Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2000-09","conditions":"Stomach Cancer, Gastric Cancer, Gastro-esophageal Junction Cancer","enrollment":25},{"nctId":"NCT00002774","phase":"PHASE2","title":"Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"1996-06","conditions":"Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)","enrollment":63},{"nctId":"NCT01755585","phase":"","title":"Irradiation Modulates the Pharmacokinetics of Anticancer Drugs","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2011-07","conditions":"Rectal Cancer, Cervical Cancer","enrollment":40},{"nctId":"NCT00123318","phase":"PHASE3","title":"A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-02","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT00268372","phase":"PHASE3","title":"S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-12","conditions":"Head and Neck Cancer","enrollment":6},{"nctId":"NCT00002524","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1993-06","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT00068575","phase":"PHASE2","title":"Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-05","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT00054054","phase":"PHASE2","title":"S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2003-04","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00563862","phase":"NA","title":"Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)","status":"TERMINATED","sponsor":"Hospital Authority, Hong Kong","startDate":"1999-07","conditions":"Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell","enrollment":465},{"nctId":"NCT00563927","phase":"NA","title":"Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"1999-03","conditions":"Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell","enrollment":340},{"nctId":"NCT01073683","phase":"PHASE2","title":"Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2010-04","conditions":"Larynx Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Radiotherapy, Cisplatin, 5-fluoruracil"],"phase":"phase_3","status":"active","brandName":"RT+CDDP/5-FU","genericName":"RT+CDDP/5-FU","companyName":"Associazione Volontari Pazienti Oncologici","companyId":"associazione-volontari-pazienti-oncologici","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death. Used for Metastatic colorectal cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}